Floatz logo

Everolimus

Hormone Receptor Positive Malignant Neoplasm of Breast

Ellipses PharmaSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hormone Receptor Positive Malignant Neoplasm of Breast cohort.

Asset / SponsorPhaseRating
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB
Capecitabine
Kristina A. Fanucci
Phase 4BBB

View all 50 →

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →